4//SEC Filing
ABERCROMBIE GEORGE B 4
Accession 0001127602-21-025252
CIK 0000882796other
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 4:14 PM ET
Size
15.2 KB
Accession
0001127602-21-025252
Insider Transaction Report
Form 4
ABERCROMBIE GEORGE B
Director
Transactions
- Exercise/Conversion
Common Stock
2021-09-10$1.71/sh+11,000$18,810→ 14,000 total - Exercise/Conversion
Automatic Stock Option Grant
2021-09-10−30,000→ 0 totalExercise: $2.91From: 2020-05-29Exp: 2029-05-29→ Common Stock (30,000 underlying) - Exercise/Conversion
Common Stock
2021-09-10$2.91/sh+30,000$87,300→ 74,000 total - Exercise/Conversion
Automatic Stock Option Grant
2021-09-10−11,000→ 0 totalExercise: $1.71From: 2013-06-30Exp: 2023-05-31→ Common Stock (11,000 underlying) - Exercise/Conversion
Common Stock
2021-09-10$3.22/sh+30,000$96,600→ 44,000 total - Exercise/Conversion
Automatic Stock Option Grant
2021-09-10−30,000→ 0 totalExercise: $3.22From: 2016-06-23Exp: 2026-05-23→ Common Stock (30,000 underlying) - Sale
Common Stock
2021-09-10$15.09/sh−74,000$1,116,660→ 0 total
Footnotes (1)
- [F1]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $14.87 to $15.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001485939
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 4:14 PM ET
- Size
- 15.2 KB